Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 9/20 | 0.89 |
| ▸ | HSD17B10 | Q99714 | 7/20 | 0.89 |
| ▸ | CYP3A4 | P08684 | 7/20 | 0.89 |
| ▸ | SMN1; SMN2 | Q16637 | 7/20 | 0.89 |
| ▸ | TP53 | P04637 | 3/20 | 0.89 |
| ▸ | ALDH1A1 | P00352 | 7/20 | 0.62 |
| ▸ | NPC1 | O15118 | 5/20 | 0.62 |
| ▸ | RAB9A | P51151 | 4/20 | 0.62 |
| ▸ | MAPT | P10636 | 7/20 | 0.58 |
| ▸ | HPGD | P15428 | 4/20 | 0.56 |
| ▸ | MEN1 | O00255 | 4/20 | 0.56 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.56 |
| ▸ | RECQL | P46063 | 2/20 | 0.56 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.56 |
| ▸ | APEX1 | P27695 | 1/20 | 0.56 |
| ▸ | BLM | P54132 | 1/20 | 0.56 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.56 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.54 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.54 |
| ▸ | NFKB1 | P19838 | 2/20 | 0.54 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29936595 | 0.94 | KDM4E (1.00) | KDM4EHSD17B10CYP3A4SMN1; SMN2TP53 | |
| SCHEMBL26145311 | 0.94 | KDM4E (1.00) | KDM4EHSD17B10CYP3A4SMN1; SMN2TP53 | |
| SCHEMBL7564891 | 0.90 | SMN1; SMN2 (0.73) | KDM4EHSD17B10CYP3A4SMN1; SMN2TP53 | |
| SCHEMBL7571074 | 0.89 | KDM4E (0.72) | KDM4EHSD17B10CYP3A4SMN1; SMN2TP53 | |
| SCHEMBL3957582 | 0.88 | SMN1; SMN2 (0.69) | KDM4EHSD17B10CYP3A4SMN1; SMN2TP53 | |
| SCHEMBL31236167 | 0.87 | SMN1; SMN2 (0.69) | KDM4EHSD17B10CYP3A4SMN1; SMN2TP53 | |
| SCHEMBL10001911 | 0.86 | KDM4E (0.68) | KDM4EHSD17B10CYP3A4SMN1; SMN2TP53 | |
| SCHEMBL26145349 | 0.86 | KDM4E (0.84) | KDM4EHSD17B10CYP3A4SMN1; SMN2TP53 | |
| SCHEMBL7502551 | 0.83 | KDM4E (0.68) | KDM4EHSD17B10CYP3A4SMN1; SMN2TP53 | |
| SCHEMBL30380532 | 0.83 | SMN1; SMN2 (0.64) | KDM4EHSD17B10CYP3A4SMN1; SMN2TP53 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20050143588-A1 | Production of isoflavone derivatives | NOVOGEN RESEARCH PTY LTD. | 2005-06-30 | — | — | US | claimed |
| US-20140107051-A1 | ISOFLAVONES FOR TREATING MUCOPOLYSACCHARIDOSES | INSTYTUT FARMACEUTYCZNY (PL) | 2014-04-17 | — | — | US | disclosed |
| US-20140107051-A1 | ISOFLAVONES FOR TREATING MUCOPOLYSACCHARIDOSES | INSTYTUT FARMACEUTYCZNY (PL) | 2014-04-17 | — | — | US | disclosed |
| US-7906660-B2 | Production of isoflavone derivatives | NOVOGEN RESEARCH PTY LTD (AU) | 2011-03-15 | — | — | US | disclosed |
| EP-2277595-A2 | Compounds for immunopotentiation | Novartis Vaccines and Diagnostics, Inc. (US) | 2011-01-26 | — | — | EP | disclosed |
| US-20100226931-A1 | Compounds for immunopotentiation | NOVARTIS VACCINES AND DIAGNOSTICS, INC. | 2010-09-09 | — | — | US | disclosed |
| US-20100226931-A1 | Compounds for immunopotentiation | NOVARTIS VACCINES AND DIAGNOSTICS, INC. | 2010-09-09 | — | — | US | disclosed |
| US-20060217564-A1 | Production of isoflavone derivatives | NOVOGEN RESEARCH PTY LTD. | 2006-09-28 | — | — | US | disclosed |
| US-20050143588-A1 | Production of isoflavone derivatives | NOVOGEN RESEARCH PTY LTD. | 2005-06-30 | — | — | US | disclosed |
| EP-1153020-A4 | PRODUCTION OF ISOFLAVONE DERIVATIVES | NOVOGEN RES PTY LTD (AU) | 2002-08-21 | — | — | EP | disclosed |
| EP-1153020-A1 | PRODUCTION OF ISOFLAVONE DERIVATIVES | Novogen Research Pty. Ltd. (AU) | 2001-11-14 | — | — | EP | disclosed |
| WO-2000049009-A1 | PRODUCTION OF ISOFLAVONE DERIVATIVES | NOVOGEN RESEARCH PTY. LTD. (AU) | 2000-08-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060217564-A1 | Production of isoflavone derivatives | CYP51A1, EGLN2, EGLN3 | KDM4E 1806/4885HSD17B10 74/4885CYP3A4 14/4885 |
| US-20100226931-A1 | Compounds for immunopotentiation | LY96, ICOS, PDCD1 | KDM4E 558/4885HSD17B10 4851/4885CYP3A4 1055/4885 |
| US-20050143588-A1 | Production of isoflavone derivatives | CYP51A1, EGLN2, EGLN3 | KDM4E 1806/4885HSD17B10 74/4885CYP3A4 14/4885 |
| US-20140107051-A1 | ISOFLAVONES FOR TREATING MUCOPOLYSACCHARIDOSES | GAA, MAN2B1, IDUA | KDM4E 4066/4885HSD17B10 192/4885CYP3A4 1840/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.